Jaguar Health 3Q 2026: Revenue $2.34M, EPS ($9.23) — 10-Q Summary
Jaguar Health reported 3Q 2026 revenue of $2.34M, down 24% YoY, with net loss narrowing to $6.31M. License revenue rose to $1.8M, while product revenue declined due to lower Mytesi sales. R&D expenses decreased slightly, and commercial costs dropped significantly after transferring Mytesi and Canalevia commercialization to Woodward. The company's pivotal pediatric MVID trial is ongoing, with clinical work continuing for crofelemer powder.
How this was made

The 30-second read
Why it matters
The disclosed revenue miss and continued net loss suggest short‑term pressure, but the Woodward license payment and trial extensions could be positive catalysts.
Market read
Primary disclosure of quarterly financials for a micro‑cap biotech; likely moves the stock on earnings reaction.
What to watch
R&D spend only slightly down; potential pipeline progress in MVID trial may offer upside.
Background
Jaguar Health is a clinical‑stage biotech focused on rare pediatric diseases. The 10‑Q reports its latest quarter results.
Ticker impact
Quarterly 10‑Q filing shows revenue down 24% YoY to $2.34M and EPS loss of $9.23 per share.
likely downside as market prices in weaker revenue and continued losses
The filing provides fresh, material financial metrics for a micro‑cap; investors typically react to revenue miss and large per‑share loss.
Market effects
Highlights ongoing weakness in niche biotech licensing revenue.
Limited to U.S. micro‑cap biotech investors.
Low; no broader market impact.
Counterpoint
If the Woodward holdback payment signals a longer‑term partnership, the stock could stabilize.
Key entities
- companyJaguar Health, Inc.
Micro‑cap biotech reporting Q3 2026 results.
- partnerWoodward
Licensee providing a $1.8M holdback payment.